Acetaminophen / Tylenol (Prenatal) Marketing & Claimant Acquisition

The litigation landscape

The prenatal acetaminophen litigation targets a wide universe of potential claimants because acetaminophen is among the most commonly used over-the-counter analgesics during pregnancy, and both ASD and ADHD are diagnoses that affect a substantial share of the pediatric population. Johnson & Johnson, as the brand-name manufacturer of Tylenol, is the anchor defendant, with generic manufacturers also named in many complaints. The core allegation is that manufacturers failed to adequately warn pregnant consumers of the potential neurodevelopmental risks associated with prenatal use.

Because the litigation involves a ubiquitous consumer product and two distinct — and separately weighted — injury categories, the case mix within any docket can vary significantly. ASD diagnoses generally represent the stronger end of the injury spectrum in this litigation; ADHD-only cases, or cases where prenatal use is difficult to document, sit at the borderline. Firms building this docket need an intake process that can efficiently sort between those tiers, and a claimant-acquisition strategy that skews toward the stronger profile from the first touchpoint.

Who a campaign targets

• Primary target — strongest campaign focus: Mothers who used acetaminophen during pregnancy and whose child has received a formal diagnosis of Autism Spectrum Disorder, particularly where use was significant and can be documented (medical records, pharmacy records, or consistent self-report).
• Secondary target — viable with strong documentation: Mothers with documented, significant prenatal acetaminophen use whose child carries an ADHD diagnosis supported by clinical records.
• Borderline — requires careful intake screening: Claimants presenting with ADHD as the sole diagnosis, or where prenatal use was minimal or difficult to corroborate. These leads require a more rigorous intake conversation before a firm commits resources.
• Campaign framing for the firm: Audience qualification should be built around three pillars — confirmed prenatal use, a documented ASD or ADHD diagnosis in the child, and the ability to substantiate the exposure period. Creative and landing-page copy should prompt self-selection on all three before a lead is passed to intake staff.

How MTAA runs Acetaminophen / Tylenol (Prenatal) campaigns

The creative challenge in prenatal acetaminophen advertising is specificity: the product is so common that nearly every mother who took any pain reliever during pregnancy will feel the ad speaks to her, regardless of whether her child has a qualifying diagnosis. MTAA addresses this by building creative that leads with the child's diagnosis — ASD or ADHD — rather than leaning on product recognition alone. Ads that open with the neurodevelopmental outcome and then connect it to prenatal acetaminophen use naturally filter for the claimant profile that matters, reducing junk volume before a single intake call is made. On Meta, this approach allows us to layer behavioral and interest-based signals around parenting communities, special-needs advocacy groups, and health-conscious parent demographics to reach mothers who are already engaged with their child's diagnosis journey.

Intake fit is a central consideration for this tort. Because the borderline tier — ADHD-only, minimal documented use — can represent a meaningful share of raw response, the handoff between ad click and intake staff needs a qualification layer: a short pre-screen that captures diagnosis type, approximate timing and frequency of acetaminophen use during pregnancy, and whether any medical documentation exists. MTAA builds this screen into the landing-page flow so that intake teams receive leads pre-sorted by case strength, not a flat list. For firms running this tort alongside a broader docket, that efficiency at the top of the funnel is what keeps cost-per-signed case manageable.